Skip to content

Clinical trial to evaluate the safety and efficacy of synthetic bone graft substitutes with growth factors for posterior lumbar interbody fusion

Clinical trial to evaluate the safety and efficacy of NOVOSIS INJECT for posterior instrumentation & posterior lumbar interbody fusion; A single site, prospective, investigator initiated trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CRIS
Registry ID
KCT0004738
Enrollment
20
Registered
2020-02-14
Start date
2020-09-26
Completion date
Unknown
Last updated
2024-03-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Medical Device : Surgery is performed in the same way as posterior lumbar interbody fusion (PLIF). Depending on the number of levels to PLIF, a 3-6 inch incision is made to allow access to the vertebr

Sponsors

The Catholic University of Korea, Seoul St. Mary's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. 19~79 years of age at the date of written informed consent 2. Patients requiring single- or double-level PLIF with pedicular fixation for the following reasons 1) Spinal Stenosis 2) Intervertebral disc disease 3) Spondylolysis or spondylolisthesis 4) Recurrent Lumbar Disc Herniation etc. 3. Signed and dated informed consent form

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women, or those who are planning pregnancy for the duration of this clinical trial or don't agree to medically accepted contraceptive methods 2. Patients with a history of malignant tumors in the past 5 years 3. Those who have removed the tumor at graft site 4. Those who are undergoing anticancer therapy 5. Those who are diagnosed with the following disease 1) Mental illness 2) Drug intoxication and alcoholism 3) Liver cancer, liver cirrhosis 4) Acute/chronic infection 5) Acute/chronic renal failure 6) Elimination Disorders 7) Active Tuberculosis 8) Rickets, osteomalacia 9) Hypopituitarism, hyperpituitarism 10) Hypothyroidism, hyperthyroidism, hypoparathyroidism, hyperparathyroidism 11) Metabolic bone disease 6. Those who can’t stop taking antithrombotic or anticoagulant before surgery 7. Uncontrolled diabetes or hypertension or blood coagulation defect 8. Hypersensitivity to rhBMP-2, Beta-tricalciumphosphate 9. Previous surgical histroy on same level 10. Immune suppression or autoimmune disease 11. Vertebral body or disc infection on surgical site 12. Severe osteoporosis on DEXA bone density test (A T-score is -3.5 under) 13. Patients who have participated in other medical device clinical trials within six months (For clinical trials of drugs, within 30 days) 14. Others, if judged by the investigator to be inappropriate for participation in this clinical trial

Design outcomes

Primary

MeasureTime frame
Fusion rates of intervertebral

Secondary

MeasureTime frame
Fusion rates of intervertebral;Rates of subsidence;Improvement compared to pre-operative VAS, ODI score

Countries

Korea, Republic of

Contacts

Public ContactKyoung-Sik Ryu

The Catholic University of Korea

nsdoc35@catholic.ac.kr+82-2-2258-6265

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 6, 2026